Haidong D Dong

List of Publications by Citations

129 papers	19,106 citations	53 h-index	138 g-index
144 ext. papers	22,017 ext. citations	9.1 avg, IF	6.12 L-index

#	Paper	IF	Citations
129	Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nature Medicine*, **2002**, 8, 793-800	50.5	3475
128	B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nature Medicine*, **1999**, 5, 1365-9	50.5	1874
127	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature*, **2018**, 560, 382-386	50.4	1058
126	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. *Nature Medicine*, **2003**, 9, 562-7	50.5	980
125	B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. *Nature Immunology*, **2001**, 2, 269-74	19.1	705
124	Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. *Cancer Research*, **2006**, 66, 3381-5	10.1	696
123	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 17174-9	11.5	657
122	Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. *Cancer Research*, **2005**, 65, 1089-96	10.1	649
121	PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. *Clinical Cancer Research*, **2007**, 13, 1757-61	12.9	431
120	B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. *Cancer Research*, **2003**, 63, 6501-5	10.1	359
119	PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. *Cancer*, **2007**, 109, 1499-505	6.4	322
118	B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. *Immunity*, **2004** , 20, 327-36	32.3	317
117	PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. *Journal of Clinical Investigation*, **2018**, 128, 580-588	15.9	259
116	B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 10391-10396	11.5	252
115	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. *Cancer Immunology Research*, **2015**, 3, 610-9	12.5	251
114	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. *Blood*, **2017**, 129, 3419-3427	2.2	244
113	Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. *Clinical Cancer Research*, **2011**, 17, 1915-23	12.9	235

112	Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. *Journal of Experimental Medicine*, **2003**, 197, 1083-91	16.6	233
111	B7-H1 pathway and its role in the evasion of tumor immunity. *Journal of Molecular Medicine*, **2003**, 81, 281-7	5.5	223
110	Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. *Blood*, **2000**, 96, 2808-2813	2.2	207
109	Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. *Gastroenterology*, **2017**, 153, 1107-1119.e10	13.3	201
108	Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. *Clinical Cancer Research*, **2008**, 14, 5150-7	12.9	200
107	Augmentation of T cell levels and responses induced by androgen deprivation. *Journal of Immunology*, **2004**, 173, 6098-108	5.3	188
106	Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. *Journal of Immunology*, **2011**, 186, 6905-13	5.3	179
105	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. *Blood*, **2001**, 97, 1809-16	2.2	179
104	B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. *Journal of Thoracic Oncology*, **2014**, 9, 1036-1040	8.9	177
103	Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. *Clinical Cancer Research*, **2007**, 13, 2075-81	12.9	168
102	Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. *Clinical Cancer Research*, **2007**, 13, 709s-715s	12.9	168
101	MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. *Journal of Immunology*, **2009**, 182, 1325-33	5.3	163
100	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. *Blood*, **2009**, 114, 2149-58	2.2	162
99	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. *Blood* , **2003**, 101, 2514-20	2.2	149
98	Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. *Cancer*, **2005**, 104, 2084-91	6.4	149
97	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. *Journal of Clinical Investigation*, **2003**, 111, 363-70	15.9	147
96	B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. *Journal of Immunology*, **2004**, 173, 5445-50	5.3	144
95	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. *Frontiers in Immunology*, **2018**, 9, 1739	8.4	112

94	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-B Activation and PD-L1 Expression. *Molecular Cell*, **2019**, 73, 22-35.e6	17.6	108
93	TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. *Journal of Immunology*, **2009**, 183, 3634-41	5.3	92
92	Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. *Clinical Cancer Research*, **2005**, 11, 5708-17	12.9	89
91	Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. *Clinical Cancer Research*, **2007**, 13, 1749-56	12.9	88
90	Soluble B7-H1: differences in production between dendritic cells and T cells. *Immunology Letters*, **2012**, 142, 78-82	4.1	86
89	Costimulation, coinhibition and cancer. *Current Cancer Drug Targets*, **2007**, 7, 15-30	2.8	79
88	PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. *Molecular Cell*, **2019**, 74, 1215-1226.e4	17.6	73
87	The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8 T Cell Fitness and Functionality. *Immunity*, **2019**, 51, 491-507.e7	32.3	70
86	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. *Frontiers in Immunology*, **2017**, 8, 961	8.4	70
85	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-B. *Cancer Research*, **2016**, 76, 239-50	10.1	62
84	CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. *JCI Insight*, **2018**, 3,	9.9	62
83	Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. *Cancer*, **2006**, 107, 46-53	6.4	61
82	Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. *Journal of Immunology*, **2007**, 179, 2860-9	5.3	61
81	Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. *Journal of Thoracic Oncology*, **2019**, 14, 276-287	8.9	61
80	PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. *Journal of Clinical Investigation*, **2017**, 127, 1960-1977	15.9	58
79	Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. *Cellular and Molecular Immunology*, **2006**, 3, 179-87	15.4	58
78	Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513. *Journal of Infectious Diseases*, **2010**, 201, 160-9	7	56
77	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. *JCI Insight*, **2016**, 1,	9.9	52

76	Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. *American Journal of Reproductive Immunology*, **2018**, 79, e12795	3.8	52
75	Contraction of T cell richness in lung cancer brain metastases. *Scientific Reports*, **2018**, 8, 2171	4.9	50
74	B7-h1 expressed by activated CD8 T cells is essential for their survival. *Journal of Immunology*, **2011**, 187, 5606-14	5.3	48
73	Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. *Journal of Clinical Investigation*, **2020**, 130, 5380-5396	15.9	48
72	Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. *Oncologist*, **2019**, 24, e1148-e1155	5.7	45
71	Immunotherapeutic approaches to hepatocellular carcinoma treatment. *Liver Cancer*, **2012**, 1, 226-37	9.1	43
70	B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. *Urology*, **2005**, 66, 10-4	1.6	42
69	ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. *OncoImmunology*, **2020**, 9, 1744980	7.2	40
68	Human bone marrow: a reservoir for "enhanced effector memory" CD8+ T cells with potent recall function. *Journal of Immunology*, **2006**, 177, 6730-7	5.3	39
67	B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. *OncoImmunology*, **2012**, 1, 1061-1073	7.2	33
66	Immunology of B7-H1 and its roles in human diseases. *International Journal of Hematology*, **2003**, 78, 321-8	2.3	33
65	BRAF-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. *Oncogene*, **2019**, 38, 6752-6766	9.2	30
64	Endogenous tumor-reactive CD8 T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. *OncoImmunology*, **2013**, 2, e23972	7.2	30
63	Targeting IFNto tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. *Nature Communications*, **2018**, 9, 4586	17.4	30
62	Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. *Blood Cancer Journal*, **2019**, 9, 22	7	28
61	The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. *Neuro-Oncology*, **2020**, 22, 967-978	1	27
60	Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. *Clinical Cancer Research*, **2018**, 24, 3299-3308	12.9	27
59	B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. *Journal of Immunology*, **2010**, 184, 5466-5474	5.3	27

58	CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. *Oncotarget*, **2016**, 7, 70223-70231	3.3	27
57	Regulation of sister chromatid cohesion by nuclear PD-L1. *Cell Research*, **2020**, 30, 590-601	24.7	26
56	B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8 T cells. *Scientific Reports*, **2016**, 6, 36722	4.9	26
55	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. *Scientific Reports*, **2019**, 9, 10677	4.9	26
54	B7-H1 expression in vestibular schwannomas. *Otology and Neurotology*, **2010**, 31, 991-7	2.6	24
53	Stem cells for murine interstitial cells of cajal suppress cellular immunity and colitis via prostaglandin E2 secretion. *Gastroenterology*, **2015**, 148, 978-90	13.3	23
52	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. *OncoImmunology*, **2017**, 6, e1356146	7.2	23
51	Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. *Heliyon*, **2018**, 4, e01039	3.6	23
50	Type I phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-B. *Oncotarget*, **2017**, 8, 42414-42427	3.3	17
49	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. *Melanoma Research*, **2020**, 30, 364-375	3.3	16
48	Immune signatures underlying post-acute COVID-19 lung sequelae. *Science Immunology*, **2021**, 6, eabk1741	48	16
47	Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells. *European Urology Focus*, **2018**, 4, 75-79	5.1	15
46	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). *Blood*, **2015**, 126, 834-834	2.2	15
45	B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System. *Frontiers in Immunology*, **2017**, 8, 1532	8.4	14
44	Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. *Blood*, **2000**, 96, 2808-2813	2.2	13
43	Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. *JAMA Network Open*, **2020**, 3, e200202	10.4	12
42	Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.. *Journal of Clinical Oncology*, **2017**, 35, 11534-11534	2.2	12
41	Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles **2020**, 8,		12

40	Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. *American Journal of Clinical Pathology*, **2017**, 148, 441-449	1.9	11
39	Radiation and immunotherapy: emerging mechanisms of synergy. *Journal of Thoracic Disease*, **2020**, 12, 7011-7023	2.6	11
38	B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation. *Cancer Immunology, Immunotherapy*, **2014**, 63, 859-67	7.4	11
37	A gender factor in shaping T-cell immunity to melanoma. *Frontiers in Oncology*, **2015**, 5, 8	5.3	11
36	PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. *JCI Insight*, **2021**, 6,	9.9	11
35	Prospective Immunophenotyping of CD8 T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. *International Journal of Radiation Oncology Biology Physics*, **2019**, 103, 229-240	4	11
34	Immunomodulatory antibody therapy of cancer: the closer, the better. *Clinical Cancer Research*, **2015**, 21, 944-6	12.9	10
33	Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. *Cancer Medicine*, **2020**, 9, 1152-1160	4.8	9
32	First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. *Oncologist*, **2018**, 23, 840-843	5.7	8
31	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). *Blood*, **2016**, 128, 4392-4392	2.2	7
30	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. *Frontiers in Immunology*, **2020**, 11, 561083	8.4	7
29	Immunotherapy in prostate cancer. *Current Urology Reports*, **2015**, 16, 34	2.9	6
28	Bim is an independent prognostic marker in intrahepatic cholangiocarcinoma. *Human Pathology*, **2018**, 78, 97-105	3.7	6
27	Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. *Future Oncology*, **2019**, 15, 2645-2656	3.6	6
26	Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. *Nature Immunology*, **2020**, 21, 365-366	19.1	5
25	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. *Blood Cancer Journal*, **2021**, 11, 86	7	4
24	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. *Journal of Clinical Investigation*, **2021**, 131,	15.9	4
23	Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. *Clinical Cancer Research*, **2021**, 27, 6376-6383	12.9	4

22	Paradox-driven adventures in the development of cancer immunology and immunotherapy. *Genes and Diseases*, **2019**, 6, 224-231	6.6	3
21	Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. *International Journal of Cancer*, **2021**, 149, 378-386	7.5	3
20	ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses. *Cancer Immunology Research*, **2021**, 9, 952-966	12.5	3
19	Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. *Cancers*, **2021**, 13,	6.6	3
18	B7-H1(PD-L1) confers chemoresistance through ERK and p38 MAPK pathway in tumor cells		2
17	Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. *Npj Precision Oncology*, **2021**, 5, 22	9.8	2
16	NKG7 is a T-cell intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy.. *Cancer Immunology Research*, **2021**,	12.5	2
15	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion		1
14	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 135.e1-135.e8	2.8	1
13	Understanding Suboptimal Response to Immune Checkpoint Inhibitors.. *Advanced Biology*, **2022**, e2101319		1
12	Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy.. *BMJ Open*, **2022**, 12, e050112	3	1
11	The Basic Concepts in Cancer Immunology and Immunotherapy **2018**, 1-19		0
10	PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-receptor I versus II.. *Cell Reports*, **2022**, 38, 110349	10.6	0
9	Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. *Nuclear Medicine and Biology*, **2021**, 100-101, 4-11	2.1	0
8	Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade.. *Advances in Radiation Oncology*, **2022**, 7, 100931	3.3	0
7	The reverse signals of costimulatory molecule B7-H1 negatively regulate memory CD8 T cell function in tumor immunity. *FASEB Journal*, **2008**, 22, 523-523	0.9	
6	A novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy.. *Journal of Clinical Oncology*, **2014**, 32, 3049-3049	2.2	
5	A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. *SOJ Immunology*, **2017**, 5, 1-5		

List of Publications

4	Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma **2009**, 367-403	
3	New Strategies to Improve Tumor Cell Vaccine Therapy **2009**, 117-131	
2	A novel method to identify and monitor endogenous tumor-reactive T cells by high expression of CD11a (LFA-1) and PD-1 (CD279) as immunologic readout for evaluating the efficacy of PD-1 blockade.. *Journal of Clinical Oncology*, **2013**, 31, 3037-3037	2.2
1	Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma. *Kidney Cancer*, **2021**, 5, 129-135	0.6